The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).
 
Scott T. Tagawa
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Bayer; Clovis Oncology; Dendreon; Endocyte; Genentech; Genomic Health; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Novartis; Novartis; Pfizer; QED Therapeutics; Sanofi; Tolmar
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi
 
Joseph Osborne
No Relationships to Disclose
 
Muhammad Junaid Niaz
No Relationships to Disclose
 
Shankar Vallabhajosula
Employment - NCM
Leadership - NCM
 
Panagiotis J. Vlachostergios
Honoraria - Dava Oncology
 
Charlene Thomas
Travel, Accommodations, Expenses - Inovio Pharmaceuticals; Nektar; Pfizer
 
Ana M. Molina
Honoraria - ASCO
Consulting or Advisory Role - Eisai; Exelixis; Janssen; Novartis
 
Cora N. Sternberg
Honoraria - Astellas Pharma; Astellas Pharma; AstraZeneca; Ipsen; Janssen; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; Incyte; Ipsen; Medscape; Merck; MSD; Novartis; Pfizer; Roche; Sanofi; UroToday
Research Funding - Aragon Pharmaceuticals (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Aveo (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Genzyme (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Myovant Sciences (Inst); Nektar (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
 
Sharon Singh
No Relationships to Disclose
 
Escarleth Fernandez
No Relationships to Disclose
 
John Babich
No Relationships to Disclose
 
David M. Nanus
Consulting or Advisory Role - Roche/Genentech
Research Funding - Boehringer Ingelheim (Inst); Novartis (Inst); Zenith Epigenetics (Inst)
 
Karla V. Ballman
Consulting or Advisory Role - Agenus; ARIAD; Medtronic; Takeda
Patents, Royalties, Other Intellectual Property - Prostate cancer signature patent (Inst)
Expert Testimony - Janssen Oncology; Janssen Oncology; Lilly
 
Neil Harrison Bander
Stock and Other Ownership Interests - BZL Biologics
Consulting or Advisory Role - ADC Therapeutics; BZL Biologics; Tarveda Therapeutics
Patents, Royalties, Other Intellectual Property - Patents to anti-PSMA antibodies assigned to Cornell Univ; Royalty--Cook Urological